In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 736-736
Abstract:
Solid tumors are usually not eradicated by conventional chemotherapy resulting in disease relapse and mortality. An intriguing example is BRCA-associated breast cancer. A genetically engineered mouse model for BRCA1-associated breast cancer (K14Cre;Brca1F/F;p53F/F), which highly resembles disease in human patients, can be used to study therapy escape and residual disease in BRCA-deficient tumors. Due to the BRCA inactivation, the tumors that arise in this model lack homologous recombination-directed DNA repair, an Achilles heel that has provided a therapeutic opportunity to eradicate tumors with DNA damage-inducing agents. Despite repeated sensitivity some residual cancer cells escape the deadly effect of anticancer therapy and lead to disease relapse. A special histopathological feature of BRCA1-mutated tumors in both humans and mice is the presence of infiltrating lymphocytes. This may be explained by the high frequency of genomic alterations of BRCA1-mutated tumors resulting in the generation of many neo-antigens. Our hypothesis is that blocking inhibitory T-cell signaling, using antibodies directed against CTLA4 and PD1, may increase the activity of the T-cell compartment towards a diverse pool of antigens, and successfully eliminate residual tumor cells in combination with DNA damage-inducing drugs. In particular, we will present data of combining CTLA4- and PD1- targeting antibodies with PARP inhibition or cisplatin to eliminate residual tumor cells in this mouse model for BRCA1-mutated breast cancer. Citation Format: Sohvi Blatter, Charlotte Guyader, Aslı Küçükosmanoğlu, Stephan Freriks, Karin de Visser, Piet Borst, Sven Rottenberg. Combining PD1- and CTLA4-inhibiting antibodies with cisplatin or PARP inhibition in an attempt to eradicate BRCA1-deficient mouse mammary tumors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 736. doi:10.1158/1538-7445.AM2015-736
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2015-736
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2015
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Bookmarklink